CI-959

• Description:

  CI-959 is an inhibitor of inflammatory cell activation. CI-959 exhibits anti-inflammatory and anti-allergic activities. CI-959 can inhibit the production of reactive oxygen species by neutrophils, as well as neutrophil adhesion, respiratory burst, and histamine release from mast cells. CI-959 can also inhibit the release of inflammatory mediators such as histamine, leukotrienes, and thromboxane from guinea-pig and human lung tissues, and effectively suppress anti-IgE-induced contractions of human bronchial smooth muscle. CI-959 can be used in the research of inflammatory and allergic diseases, such as asthma[1][2][3].

• UNSPSC:

  12352005

• Target:

  Histamine Receptor; Reactive Oxygen Species (ROS)

• Related Pathways:

  GPCR/G Protein; Immunology/Inflammation; Metabolic Enzyme/Protease; Neuronal Signaling; NF-κB

• Field of Research:

  Endocrinology; Inflammation/Immunology

• Smiles:

  COC1=CC=C2C(C(OC(C)C)=C(C(NC3=NN=NN3)=O)S2)=C1.[Na]

• Molecular Formula:

  C14H15N5NaO3S

• Molecular Weight:

  356.36

• References & Citations:

  [1]Adolphson RL, et al. CI-959, a new, potential antiallergic drug, inhibits mediator release from lung and contractions of human airways in vitro. Int Arch Allergy Appl Immunol. 1990;93 (2-3) :267-71.|[2]Burke SE, et al. Reduction of canine myocardial infarct size by CI-959, an inhibitor of inflammatory cell activation. J Cardiovasc Pharmacol. 1992 Oct;20 (4) :619-29.|[3]Low J, et al. Cytoprotective effects of CI-959 in the rat gastric mucosa: modulation of leukocyte adhesion. Gastroenterology. 1995 Oct;109 (4) :1224-33.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  Phase 1

• CAS Number:

  [104795-68-8]